JPS58150585A - Preparation of 1,3-dioxolen-2-one derivative - Google Patents

Preparation of 1,3-dioxolen-2-one derivative

Info

Publication number
JPS58150585A
JPS58150585A JP58013076A JP1307683A JPS58150585A JP S58150585 A JPS58150585 A JP S58150585A JP 58013076 A JP58013076 A JP 58013076A JP 1307683 A JP1307683 A JP 1307683A JP S58150585 A JPS58150585 A JP S58150585A
Authority
JP
Japan
Prior art keywords
reaction
dioxolen
compound shown
ampicillin
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP58013076A
Other languages
Japanese (ja)
Other versions
JPH0258271B2 (en
Inventor
Fumio Sakamoto
坂本 文夫
Shoji Ikeda
池田 昇司
Goro Tsukamoto
悟郎 塚本
Isamu Uchiumi
勇 内海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanebo Ltd
Original Assignee
Kanebo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanebo Ltd filed Critical Kanebo Ltd
Priority to JP58013076A priority Critical patent/JPS58150585A/en
Publication of JPS58150585A publication Critical patent/JPS58150585A/en
Publication of JPH0258271B2 publication Critical patent/JPH0258271B2/ja
Granted legal-status Critical Current

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

NEW MATERIAL:A compound shown by the formulaI(R1 is H, lower alyl, or aryl; R2 is H or R2 and R1 are linked to carbon chain in cyclic state; X is halogen). EXAMPLE:4-Chloromethyl-1,3-dioxolen-2-one. USE:Useful especially as a modifying agent for a prodrug of a medicine. PROCESS:A compound shown by the formula II is reacted with preferably 0.8- 1.2mol halogenating agent (e.g., Cl, Br, etc.) at room temperature or usually under conditions to produce a radical under heating, to give a compound shown by the formulaI. Ultraviolet light is irradiated during the reaction, or a free- radical initiator such as alpha,alpha'-azobisisobutyronitrile, etc. is added to the reaction system, so that the reaction is preferably promoted. An ester and an ether derived from the compound shown by the formulaIare stable in a neutral medium, but it is easily hydrolyzed under common alkali hydrolyzing conditions, so it is useful as a reagent for introducing a protecting group in chemical reactions.

Description

【発明の詳細な説明】 本発明は医薬品のプロドラッグ用修飾剤として有用な新
規1.3−ジオキソレン−2−オン誘導体の製造法に関
する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method for producing novel 1,3-dioxolen-2-one derivatives useful as modifiers for prodrugs of pharmaceuticals.

医薬品の中FcFi、高い薬理活性を有しながら、化学
的な不安定性や生物学的利用率(パイオアペラビリティ
−)の不良等のために、医薬品としての有用性を充分に
発揮し得ないものがあり、又このような欠点を改善する
方法の1つとして化学的修飾による!ロドラッグがある
Among pharmaceuticals, FcFi is a substance that has high pharmacological activity but cannot fully demonstrate its usefulness as a pharmaceutical due to chemical instability or poor bioavailability. However, one way to improve these drawbacks is through chemical modification! There is a rod drug.

例えは腸管吸収率の低い薬物を化学的に部分修飾して腸
v吸収を^め、生体内で化学的・生物学的作P+iによ
り元の薬物に復元せしめて、その薬物本来のJlkl情
理を発現させるやり方である。
For example, a drug with a low intestinal absorption rate can be partially modified chemically to increase intestinal v absorption, and then restored to its original state in vivo through chemical and biological action P+i, thereby preserving the original Jlkl properties of the drug. This is the way to express it.

従来から、この目的のために種々の修飾基が提案されて
いるが、それらを用いたゾロドラッグの化学的安定性、
生体a〆の元の薬物への復元性、わるいは修飾基が一友
らす副作用等の点で未だ満足の域に達していない。
Various modification groups have been proposed for this purpose, but the chemical stability of zolodrugs using them,
The level of satisfaction has not yet been reached in terms of the reversibility of biogenic acetate to the original drug, and the side effects caused by modifying groups.

本発明は、特に医薬品のゾロドラッグ用の修飾剤として
有用かつ新規な一般式CI〕で示される1、S−ジオキ
ソレン−!−オン誘導体の製造法〔式中、R1は水素原
子、低級アルキル基又はアリール話を示し、XFiハロ
rン原子を示す。R1は水素原子であるか又はR1と炭
素鎖で環状に結合している〕 一般式〔夏〕で示される1、3−ジオキソレン−2−オ
ン騎導体L1いずれも文献未記載の新規化合物であり、
具体例を挙げると4−クロルメゾルー1.3−ジオキソ
レン−2−オン、4−ブロモメチル−1,3−ジオキソ
レン−2−オン、4−クロロメチを−5−メチル−1,
3−ジオキソレン−2−オン、4−ブロモメチル−5−
)fルーl、3−ジオキソレン−2−オン、4−ヨード
メチル−5−メチル−1,3−ジオキソレン−2−オン
、4−クロロメチル−5−フェニル−1゜a−ジオキソ
レン−2−オン、4−/四モメチル=5−フェニルー1
.3−ジオキソレン−2−オン、3−クロロ−1,2−
カルボニルジオキシシクロヘキセン、3−プ筒モー1.
2−カルポニルゾオキシシクロヘキセン、3−プルモー
1.2−カルボニルジオキシシクロオクテン等である。
The present invention provides 1,S-dioxolene-! represented by the general formula CI], which is particularly useful as a modifier for zolodrugs of pharmaceuticals. -Production method of -one derivative [In the formula, R1 represents a hydrogen atom, a lower alkyl group or an aryl group, and represents an XFi halo r atom. R1 is a hydrogen atom or is cyclically bonded to R1 through a carbon chain] 1,3-dioxolen-2-one conductor L1 represented by the general formula [Natsu] is a new compound that has not been described in any literature. ,
Specific examples include 4-chloromethol-1,3-dioxolen-2-one, 4-bromomethyl-1,3-dioxolen-2-one, 4-chloromethy-5-methyl-1,
3-Dioxolen-2-one, 4-bromomethyl-5-
) fl, 3-dioxolen-2-one, 4-iodomethyl-5-methyl-1,3-dioxolen-2-one, 4-chloromethyl-5-phenyl-1゜a-dioxolen-2-one, 4-/tetramomethyl=5-phenyl-1
.. 3-Dioxolen-2-one, 3-chloro-1,2-
Carbonyldioxycyclohexene, 3-meryl 1.
These include 2-carponylzooxycyclohexene, 3-pulmo-1,2-carbonyldioxycyclooctene, and the like.

仁れら1,3−ソオキンレンー2−オン訪導体は、いず
れもカルざン酸触、チオカルがンWk、類、フェノール
@勢と容易に反応して対応するエステル型化合物および
エーテル型化合物を生成するが、これらエステル型化合
物およびエーテル源化合物は中性および酸性媒質中で安
定であり、又通常の化学反応におけるアルカリ加水分離
条件下では容易に加水分解されるにかかわらず、腸液に
相幽するアルカリ性媒質中では比較的に安定でめって、
しかも生体内酵素の存在下では容易に加水分触されて元
の化合物に復元する。
Nire et al.'s 1,3-soquinren-2-one visiting conductors all react easily with carboxylic acid catalysts, thiocarganes, and phenols to produce corresponding ester-type and ether-type compounds. However, these ester-type compounds and ether source compounds are stable in neutral and acidic media, and although they are easily hydrolyzed under alkaline hydrolysis conditions in normal chemical reactions, they do not phase into the intestinal fluid. Relatively stable in alkaline media and rarely
Moreover, in the presence of in vivo enzymes, it is easily hydrolyzed and restored to its original compound.

例えば、カルボン酸基を持つペニシリン類と一般式〔I
〕でボされる1、3−ジオキソレン−2−オンI導体を
反応させると対応するエステルが生成し、このエステル
は胃液およびに液内では安定であって、腸管からむ易に
吸収されると共に生体内で容易に加水分解されて元のペ
ニシリンに復元する。このように、一般式[13で示さ
れるl。
For example, penicillins having a carboxylic acid group and general formula [I
] The reaction of the 1,3-dioxolen-2-one I conductor produces the corresponding ester, which is stable in gastric and gastrointestinal fluids, easily absorbed from the intestinal tract, and produced. It is easily hydrolyzed in the body and restored to its original form as penicillin. In this way, l represented by the general formula [13].

3−ジオキソレン−2−オン誘導体は特に医薬品の)誼
ドラッグ用修飾剤として有用で多る。なお、カルボン酸
類およびフェノール類と該1.3一/オキソレンー2−
オン篩導体から導かれるエステル類およびエーテル類は
、前述のとおシ中性媒質および酸性線質中で安定でおる
が、通常のアルヵリカ11水分解条件下でFib易に加
水分解を受けるので、該1.3一ジオキソレンー2−オ
ン篩導体は化学反応における保験基の導入試薬としても
有用である。
3-Dioxolen-2-one derivatives are often useful as drug modifiers, especially for pharmaceuticals. In addition, carboxylic acids and phenols and the 1.3-/oxolene-2-
Esters and ethers derived from on-sieve conductors are stable in neutral media and acidic rays as described above, but they are easily hydrolyzed by Fib under normal alkali-11 water decomposition conditions. 1.3-Dioxolene-2-one sieve conductors are also useful as reagents for introducing protective groups in chemical reactions.

以下に#l、3−ジオキソレンー2−オン64体の有用
性を示す実験データー金挙げる。
Below, we list experimental data showing the usefulness of 64 #l, 3-dioxolene-2-ones.

〔経口投与時の血中濃度〕[Blood concentration during oral administration]

1、供試化合物 A アンピシリン(5−メチル−2−オキソ−1,3−
&オキソシン−4−イル)メチルエステル−酸塩(後述
の参考例3に従ってアンピシリン三水和物と4−ブロモ
メチル−5−メチル−1゜3−ノオキソレンー2−オン
とから合成した。)B アンピシリンフタリジルエステ
ル塩酸塩(公知のアンピシリンエステル、対照化合物)
Cアンピシリン三水和物(対照化合物)2 試験方法 一夜組0食した4退会マウス1ddY糸、体重的202
1一群5匹)にアンピシリン換算5αO〜/ Ky札尚
の供試化合物(アンピシリン換算で濃度5jv/7!の
水溶液約0.!−)を経口投与し、経時的に採血して血
清中のアンピシリン濃度をバイオアッセイ法によって5
測定し、各供給化合物の血清中アンピシリン濃度の相対
比を求めた。
1. Test compound A ampicillin (5-methyl-2-oxo-1,3-
&oxocin-4-yl) methyl ester acid salt (Synthesized from ampicillin trihydrate and 4-bromomethyl-5-methyl-1°3-nooxolen-2-one according to Reference Example 3 described below.) B Ampicillin phthalate Dyl ester hydrochloride (known ampicillin ester, reference compound)
C Ampicillin trihydrate (control compound) 2 Test method: 4 withdrawal mice with 0 meals per night 1 ddY thread, weight 202
A test compound (an aqueous solution with a concentration of 5 jv/7! in terms of ampicillin, approximately 0.!-) was orally administered to ampicillin equivalents of 5 αO~/1 group (5 animals), and blood was collected over time to determine the ampicillin level in the serum. 5 concentration by bioassay method.
The relative ratio of serum ampicillin concentration of each supplied compound was determined.

3、結果 第 1 表 第1衆から明らかなように、該l、3−ジオキルンー2
−オンb導体から誘導されたアンピシリンエステル(4
は、容易に吸収されて生体内で元のアンピシリンIK−
復元し、アンピシリン9おヨヒ公知のアシピシリンエス
テル(ロ)に比し長時間にわたり^い血中アンピシリン
濃[k示す。
3. Results 1 As is clear from Table 1, the l,3-diokiln-2
- ampicillin ester derived from one b conductor (4
is easily absorbed in vivo to form the original ampicillin IK-
Ampicillin 9 is restored and maintains a higher blood ampicillin concentration over a longer period of time than the known acipicillin ester (b).

〔酸性媒質(人工両液に該当)中での加水分解〕L 供
試化合物   前記AおよびB ′L vc一方法 1000wt甲に食塩2−Of、10To塩酸24−、
ペプシン121を冨む酸性媒質(p#i、lに供純化賞
物を浴解し、37Cに振叡しつつ経時的にサンシリンダ
して連孔分配カラムを用いた尚速液体クロマト法により
、各供試化付物のピーク尚の諷少からその加水分解率を
求めた。
[Hydrolysis in acidic medium (corresponding to both artificial liquids)] L Test compound A and B'L vc method 1000wt A to 2-Of salt, 10To hydrochloric acid 24-,
The purified product was dissolved in an acidic medium (p#i, l) containing pepsin 121, shaken in 37C, and heated in a sun cylinder over time, using an instant liquid chromatography method using a continuous hole distribution column. The hydrolysis rate of each sample was determined from the magnitude of the peak.

λ k  釆 第2表 !!2鰍に示すとおり、酸性媒質中ではAはBに比し是
かに安定である。
λ k Table 2! ! As shown in Figure 2, A is definitely more stable than B in an acidic medium.

〔塩基性媒質(人工腸液に該当)中での加水分解〕L 
供試化合物   前記AおよびB 2 試験方法 1000−中に燐酸二ナトリ9ム3&8fS 10%−
酸乙Osd、ノ臂ンクレアテン2.8fを含む塩基性媒
質(p7/7.s)中に供試化合物を溶解し、前記の酸
性媒質の場合とPj様にして、各供試化合物の加水分解
率を求め危。
[Hydrolysis in basic medium (corresponding to artificial intestinal fluid)] L
Test compound Disodium phosphate 9M 3&8fS 10% in A and B 2 Test Method 1000-
The test compound was dissolved in a basic medium (p7/7.s) containing 2.8f of acid and createne, and the hydrolysis of each test compound was carried out in the same manner as in the case of the acidic medium described above. I'm in danger of finding a rate.

ま結果 第3表 絽3衣にボすように、塩基性媒質中ではAIdBに比し
安建である。
As shown in Table 3, it is less expensive than AIdB in a basic medium.

〔その他〕〔others〕

前記Aの毒性(Lへ、)をマワス(4a令ddY糸)上
用いて祠べた結果は次のとおシである。
The results of using the toxicity of A (to L) on Mawas (4a age ddY yarn) are as follows.

経口投与〉へoooダ/Kf、腹腔的投与L430hi
/ト11靜脈内投与557■/に4゜以上のとおり該1
.3−ソオキソレ:/−2−,:をン島導体は医薬のプ
ロドラッグ用修飾剤として極めて有用であるが、かかる
有用性は従来の知見からは全く予測し得ないところであ
る。
Oral administration> oooda/Kf, intraperitoneal administration L430hi
/ 11 Intravenous administration 557■ / as above 4°
.. Although the 3-sooxole:/-2-,:-conductor is extremely useful as a modifier for pharmaceutical prodrugs, such usefulness cannot be predicted at all from conventional knowledge.

すなわち、本発明の出発原料である4−メチル−5−フ
ェニル−1,3−ソオキルンー2−オン、4.5−ジメ
チル−1,3−ノオキンレンー2−オン尋がリーピッヒ
ズ噛アンナレン・デル・ヘミ−1第764巻、116〜
124頁(1972年)、テトシヘドロン・レターズ、
1972年、1701〜1704頁および米国特軒第ミ
o2偽290号公報に開示されているが、それらから尋
かれる一般式(1’lで示される該1.3一ジオキソレ
ンー2−オン誘導体については伺勢の記載もない。又、
リービッヒズ・アンナレン・デル−へし−1977年、
2丁〜32負には、4.5−ジメチル−1,3−ジオキ
ソレン−2−オンをブロム化することにより、重合体製
造用中間原料である4、5−ビス(ブロモメチル)−1
,3−ジオキソレン−2−オンが得られる旨記載されて
いるが、Kl 、3−ジオキソレン−2−オン誘導体の
製法に関しては具体的な記載がないし、又、その用途に
関しても何らの示唆もない。
That is, 4-methyl-5-phenyl-1,3-sokylin-2-one and 4,5-dimethyl-1,3-sokylene-2-one, which are the starting materials of the present invention, are obtained from Liepiig's chemical compound. 1 Volume 764, 116~
124 pages (1972), Tetoshihedron Letters,
1972, pp. 1701-1704 and U.S. Tokken No. 290, for the 1.3-dioxolene-2-one derivative represented by the general formula (1'l), There is no record of the visit.Also,
Liebig's Annalen der Heshi-1977,
For 2 to 32 negative, 4,5-bis(bromomethyl)-1, which is an intermediate raw material for polymer production, is produced by brominating 4,5-dimethyl-1,3-dioxolen-2-one.
, 3-dioxolen-2-one can be obtained, but there is no specific description of the method for producing Kl, 3-dioxolen-2-one derivatives, and there is no suggestion regarding its use. .

本発明の1,3−ジオキソレン−2−オンI%導体の製
造法は、一般式 〔式中、R1、R鵞は前記1(−同じ〕で示される化合
物に、室温もしくは一般には加熱条件下のラジカル発生
条件下で、好ましくは0.8〜1.2モルのハayンダ
ンを反応させることによって達せられる。
The method for producing the 1,3-dioxolen-2-one I% conductor of the present invention involves adding a compound represented by the general formula [where R1 and R are the same as 1] above at room temperature or generally under heating conditions. This is achieved by reacting preferably 0.8 to 1.2 moles of hydrogen under radical generating conditions.

出発原料でおる一般式〔璽〕の化合物社、例えハリービ
ツヒズ・アンナレン・デル・へ<−1g764巻、11
6〜124頁(19?21$)、テトラヘト買ン・レタ
ーズ、1972年、1701〜l?04頁、および米国
特許11i&0 ! a$+ 90号公報等に開示され
ている公知の方法に従って合成することができる。
Compounds of the general formula [seal] with starting materials, e.g. Harry Bitzhs Annalen Der <-1g 764 volumes, 11
pp. 6-124 ($19?21), Tetrahet Buyer Letters, 1972, 1701-l? Page 04, and US Patent 11i & 0! It can be synthesized according to the known method disclosed in A$+ No. 90 and the like.

ハロダン化剤としては、例えば塩素、臭素、N−ブロモ
フタル酸イミド、N−ブロモコハク酸イ建ド、N−クロ
ロフタル酸イミド、N−クロロコハク酸イイド勢がある
。一般式〔扉〕で示される原料とハロダン化剤との反応
を進めるために、反応中紫外線を照射するか、或は反応
液にα、α′−アゾビスイソブチロニトリル、過e化ベ
ンゾイルのようなラジカル化剤を用いることが好ましい
Examples of the halodating agent include chlorine, bromine, N-bromophthalimide, N-bromosuccinimide, N-chlorophthalimide, and N-chlorosuccinimide. In order to proceed with the reaction between the raw material represented by the general formula [door] and the halodanizing agent, ultraviolet rays are irradiated during the reaction, or α,α'-azobisisobutyronitrile, benzoyl peroxide is added to the reaction solution. It is preferable to use a radicalizing agent such as.

反応溶媒は、原料の性質郷に応じて適当なものが選択さ
れ、例えば塩化メチレン、クロルホルム、四塩化炭素、
四塩化エチレン、ベンゼン尋が挙ケられる。
An appropriate reaction solvent is selected depending on the properties of the raw materials, such as methylene chloride, chloroform, carbon tetrachloride,
Examples include ethylene tetrachloride and benzene.

又、一般式〔!〕においてXが沃素原子である化合%j
は、常法に従って、一般式〔1〕においてXが臭素原子
又は塩素原子である化合物に沃化ナトリウム又は沃化カ
リウムを作用させて得ることができる。
Also, general formula [! ] in which X is an iodine atom %j
can be obtained by reacting a compound of general formula [1] in which X is a bromine atom or a chlorine atom with sodium iodide or potassium iodide according to a conventional method.

以下実施例および参考例を挙げて本発明を具体的に貌明
する。
The present invention will be specifically explained below by giving examples and reference examples.

4−ブロモメチル−5−フェニル−1,3−ジオキソレ
ン−2−オンの製造; 4−メチル−5−フェニル−1,3−ジオキソレン−2
−オン(リービッヒズ・アンナレン・デル・ヘミ−1第
764巻、116〜124頁、1972年に従って合成
した)2.4f(ao13@モル)を四塩化炭素15(
Idに浴解し、これに2.9f(ao1g2モル)のN
−ブロモコハク酸イミドお工び触媒量のα、α′−アゾ
ビスイソブチロニトリルを加え、90分間加熱還流した
。反応液を半tまで濃縮し不溶物を戸別し、P液を磯縮
し残渣をベンゼンとシクロヘキサンの混液から再結晶し
無色針状結晶、融点9α5〜st、scの目的@2.3
?(収率66%)を得た。
Production of 4-bromomethyl-5-phenyl-1,3-dioxolene-2-one; 4-methyl-5-phenyl-1,3-dioxolene-2
-one (synthesized according to Liebig's Annalen der Hemi-1 Vol. 764, pp. 116-124, 1972) 2.4f (ao13@mole) was dissolved in carbon tetrachloride 15 (
Id was bath-dissolved, and 2.9f (1 g of ao, 2 moles) of N was added to it.
- Bromosuccinimide A catalytic amount of α,α'-azobisisobutyronitrile was added and heated under reflux for 90 minutes. The reaction solution was concentrated to half a ton, the insoluble matter was separated, the P solution was condensed, and the residue was recrystallized from a mixture of benzene and cyclohexane to produce colorless needle-like crystals, melting point 9α5~st, sc purpose @ 2.3
? (yield: 66%).

元素分析、分子式C,@H,Bf″O1:理論m(%)
C,47,09:#、2.77:Br3133゜実験値
(%)Ct47y!!:B、5L64:By。
Elemental analysis, molecular formula C, @H, Bf″O1: Theory m (%)
C, 47, 09: #, 2.77: Br3133° Experimental value (%) Ct47y! ! :B, 5L64:By.

31.29゜IR(KBr 、 yca−”  )  
: 1825付近(カル〆ニル)。NMR(CCj、)
J(ppm)Htas (−C:H,By、a)、7.
40 (ヘ7セ7壊。
31.29゜IR (KBr, yca-”)
: Around 1825 (Carl〆nil). NMR (CCj,)
J (ppm) Htas (-C:H, By, a), 7.
40 (He 7 se 7 break.

a) 実施例2 4−ブロモメチル−5−メチル−1,3−ジオΦツレ7
−2−オンの製造: 4.5−ジメチル−1,3−ジオキソレン−2−オン(
テトラヘドロン・レターズ、19724E、1701−
1704真に従って合成した)142t(α03モル)
を四塩化炭素150mに溶解し、これに5.34 f 
(a 03モル) (DN−)o%コハク戚イミドおよ
び触媒量のα、α′−アゾビスイソブチロニトリルを加
え、15分間加熱還流した。
a) Example 2 4-bromomethyl-5-methyl-1,3-dio Φsure 7
-2-one production: 4,5-dimethyl-1,3-dioxolen-2-one (
Tetrahedron Letters, 19724E, 1701-
142t (α03 mol) synthesized according to 1704
was dissolved in 150 m of carbon tetrachloride, and 5.34 f
(a 03 mol) (DN-)o% succinimide and a catalytic amount of α,α'-azobisisobutyronitrile were added, and the mixture was heated under reflux for 15 minutes.

反応液を半tまで禰−し不f#物を戸去した恢、P液を
遺14 L、た。シラツゾ状の残渣を減圧蒸留し無色液
体、沸点115〜l 20 C/ 5 UI Hgの目
的物4.2f(収率73%)を得た。
After reducing the reaction solution to half a ton and removing the waste material, 14 L of P solution remained. The cilantro-like residue was distilled under reduced pressure to obtain the desired product 4.2f (yield 73%) as a colorless liquid with a boiling point of 115 to 120 C/5 UI Hg.

元素分析、分子式C@H@BrOs =理論値(%):
C,31,111:#、!61:Br、41.40゜実
Mfl(%):C,31,30#、149  By。
Elemental analysis, molecular formula C@H@BrOs = theoretical value (%):
C,31,111:#,! 61: Br, 41.40° Actual Mfl (%): C, 31,30#, 149 By.

41.31.  I7i:(=−ト、 ν(+11−”
):1825付近(カルがニル) NMR(CCI、)δ(pp禦):λ1O(−CB、、
a)、4、1 O(−CM!Br、 a ) 実施例3 4−ブロモメチル−1,3−ジオキソレン−2−オンの
製造: 4−メチル−1,3−ジオキルン−2−オン(米国特許
第3020.290号に従って合成した)&6t(α0
86モル)を四塩化炭素200mに酊解し、これに17
.8 F (0,O1モル)のN−ブロモコハク酸イミ
ドおよび触媒量のα、α′−アゾビスイソプチロニトリ
ルを加え90分間加熱還Hシ、た。以下実施例2と同様
に処理して無色液体、沸点94t?/3■H7)の目的
物5.2f(収率316%)を得た。
41.31. I7i: (=-t, ν(+11-"
): around 1825 (carganyl) NMR (CCI,) δ (pp): λ1O (-CB,,
a), 4,1 O(-CM!Br, a) Example 3 Preparation of 4-bromomethyl-1,3-dioxolen-2-one: 4-Methyl-1,3-diokyln-2-one (U.S. Pat. 3020.290)&6t(α0
86 mol) was dissolved in 200 m of carbon tetrachloride, and 17
.. 8F (0.01 mol) of N-bromosuccinimide and a catalytic amount of α,α'-azobisisobutyronitrile were added and heated to reflux for 90 minutes. The following treatment was carried out in the same manner as in Example 2 to obtain a colorless liquid with a boiling point of 94 tons. /3■H7) target product 5.2f (yield 316%) was obtained.

元素分桁、分子式C,H3BrO,:埋紬値(%)二C
,2&84:#、119:By、44g!、実験値(%
) :c 、 26.94 、fi、 Lu1l :B
r 。
Element digit, molecular formula C, H3BrO,: Buried value (%) 2C
, 2 & 84: #, 119: By, 44g! , experimental value (%
) :c, 26.94, fi, Lu1l :B
r.

4460゜IRに−ト、シC11−”):1830付近
(カルlニル) NMR(CCJ4)δ(ppm) : 410 (−C
H,BT。
4460° IR, C11-''): around 1830 (carnyl) NMR (CCJ4) δ (ppm): 410 (-C
H, B.T.

1)、?、 G O(= CM−0−、a )実施例4 3−ブロモー1.2−カルがニルジオキシシクロヘキセ
ンの製造: 1.2−カルボニルジオキシシクロヘキセン(テトラヘ
ドロン・レターズ、1972年、1701−1704j
jに従って合成した)2.15?(0,015モル)を
四塩化炭素80−に浴解し、コレに2.3f(α013
モル)のN−ブロモコハク酸イミド及び触媒量のα、α
′−アゾビスイソブチロニトリルγ加え20分間加熱還
流した。反応液を冷@許過し、F液を低融で真綿し目的
の粗生成、吻(淡褐色液体)&2vを得た。JR(ニー
m)、L3−40(*状水素、m) この目的物の粗生成物は不安定であるので、単嘔鞘製す
ることなくアンピシリンと反応させてアンピシリンエス
テルを得た(参考?l11参@)。
1),? , G O (= CM-0-, a ) Example 4 Preparation of 3-bromo 1,2-calyldioxycyclohexene: 1,2-carbonyldioxycyclohexene (Tetrahedron Letters, 1972, 1701- 1704j
synthesized according to j) 2.15? (0,015 mol) was dissolved in 80-carbon tetrachloride, and 2.3f (α013
moles) of N-bromosuccinimide and catalytic amounts of α, α
'-Azobisisobutyronitrile γ was added and heated under reflux for 20 minutes. The reaction solution was cooled and filtered, and the F solution was swabbed with a low melting point to obtain the desired crude product, 2V (light brown liquid). JR (nee m), L3-40 (*-like hydrogen, m) Since the crude product of this target product is unstable, it was reacted with ampicillin without making a single oyster to obtain ampicillin ester (reference? See l11@).

(参考例1) アンピシリン三水和物500jVt−ジメチルホルムア
ミド6−に分散させ、これに塩炭酸カリウム125W1
gをυ■えてOCに冷却し、史にインtアルデヒド0.
25−を7l口えてOCで25時間攪拌した。
(Reference Example 1) Ampicillin trihydrate was dispersed in 500jVt-dimethylformamide 6-, and potassium salt carbonate 125W1 was added to it.
υ■, cooled to OC, and added 0.0 g of int aldehyde.
7 liters of 25- were added and stirred for 25 hours under OC.

次に電炭酸カリウム125M9と3−ブロモー1゜2−
カルがニルジオキシシクロヘキセン250■(実施例4
で侍九粗生成物)を加え更にoCで3時間攪拌し九0反
応終了後、反応液を氷水中に注そぎ込み、析出する固型
物を酢酸エチル30−で抽出し、有機層を水!〇−で3
回洗浄し、無水硫酸マダネシウムで転轍し喪後、酢酸エ
チルを減圧上留去し黄色シラツブを得喪。
Next, potassium electrocarbonate 125M9 and 3-bromo 1゜2-
Cal is nyldioxycyclohexene 250■ (Example 4
Samurai (crude product) was added thereto, and the mixture was further stirred for 3 hours at oC. After the reaction was completed, the reaction solution was poured into ice water, the precipitated solid was extracted with ethyl acetate, and the organic layer was extracted with water. ! 〇- and 3
After washing twice and replacing with anhydrous madanesium sulfate, ethyl acetate was distilled off under reduced pressure to obtain a yellow slag.

上記の様にして得られたシラツブ状残渣をアセトニトリ
ル4sdKil解し希塩酸でpH16に調整しoCで3
0分間攪拌し九、これに水10mgを加え減圧下アセト
ニトリルを留去し、水層を酢酸エチルでくりかえし洗浄
した後食塩を飽和させ析出する油状物質を塩化メチレン
se−で抽出し、飽和食塩水で洗浄した。塩化メチレン
溶液を無水硫酸ナトリウムでt燥した後半tまで濃縮し
、インゾロピルアルコール3・−を加え再び減圧濃縮す
ると淡黄色固体が得られた。
The slag-like residue obtained as above was dissolved in acetonitrile with 4sdKil, adjusted to pH 16 with diluted hydrochloric acid, and heated at oC for 3 hours.
After stirring for 0 minutes, 10 mg of water was added and the acetonitrile was distilled off under reduced pressure. The aqueous layer was washed repeatedly with ethyl acetate, and then the salt was saturated. The precipitated oily substance was extracted with methylene chloride se-, and saturated brine Washed with. The methylene chloride solution was dried over anhydrous sodium sulfate, concentrated to the latter half of t, and inzolopyl alcohol 3.- was added and concentrated again under reduced pressure to obtain a pale yellow solid.

この固体をP敗しインゾロピルアルコール、エーテルで
洗浄しアンピシリン(2,3−カルが二ルソオキシー2
−7クロヘチセニル)エステル塩酸塩の無色無定型固体
256■を得た。融点140C(分解)。IR(KEr
 、Mca−”  ):1830.1780,1750
(力A/ zニル) 。
This solid was washed with inzolopyl alcohol and ether, and then ampicillin (2,3-cal dirusoxy-2
256 ml of colorless amorphous solid of -7 chlorohethycenyl) ester hydrochloride was obtained. Melting point 140C (decomposed). IR(KEr
, Mca-”):1830.1780,1750
(Force A/znil).

169G(アミド) 上記アンピシリンエステル塩酸塩を40%マウス血液中
で37Cで10分間インキュベートしたのちバイオオー
トグラフィーを実施したところ、該エステルは全てアン
ピシリンに転化している事が判った。
169G (amide) When the above ampicillin ester hydrochloride was incubated in 40% mouse blood at 37C for 10 minutes and then subjected to bioautography, it was found that all of the ester was converted to ampicillin.

(参考例2) 参′4例1と同様にして、アンピシリン三水和物と4−
ブロモメチル−5−フェニル−1、3−1/オキソレン
−2−オンからアンピシリン(5−)ユニルー2−オキ
ソー1.3−ノオキソレンー4−イル)メチルエステル
塩酸塩を得た。
(Reference Example 2) Ampicillin trihydrate and 4-
Ampicillin (5-)uni-2-oxo-1,3-nooxolen-4-yl) methyl ester hydrochloride was obtained from bromomethyl-5-phenyl-1,3-1/oxolen-2-one.

収率46−4%、無色無定型固体、融点1401:”(
分解)、IR(KBr、vx−”  ):1830゜1
785.17SO(カルボニルLtgs。
Yield 46-4%, colorless amorphous solid, melting point 1401:"
decomposition), IR (KBr, vx-”): 1830°1
785.17SO (Carbonyl Ltgs.

(アミド) このアンピシリン(S−フエ、ニル−2−オキソ−1,
3−ジオキソレン−4−イル)メチルエステル塩酸塩を
40%マウス血液中で3丁CK5分間イ/キュベートし
たのちバイオオートグラフィーを実施し九ところ該エス
テルは全てアンピシリンに転化している事が判った。
(amide) This ampicillin (S-hue, nyl-2-oxo-1,
After incubating 3-dioxolen-4-yl) methyl ester hydrochloride in 40% mouse blood for 5 minutes, bioautography was performed and it was found that all of the ester was converted to ampicillin. .

(参考f13) 参考iQ1と同様にして、アンピシリン三水和物と4−
ブロモメチル−暴−メチル−1,8−ジオキソレアー2
−オンからアンピシリン(i−メチル−2−オキソ−1
,S−8/オキソレン−4−イル)メチルエステル塩酸
塩を得た。
(Reference f13) Ampicillin trihydrate and 4-
Bromomethyl-bromo-methyl-1,8-dioxolea 2
-one to ampicillin (i-methyl-2-oxo-1
, S-8/oxolen-4-yl) methyl ester hydrochloride was obtained.

収率5α6%、無色無定型固体。Yield 5α6%, colorless amorphous solid.

融点141Cより着色し始め145Cで発泡する。It begins to color at the melting point of 141C and foams at 145C.

IR(KBr 、Vex−”  ):1g25.178
5 。
IR (KBr, Vex-”): 1g25.178
5.

1750(カルがニル)、1690(アミド)このアン
ピシリン(5−メチル−2−オキソ−1,3−f/オキ
ソレンー4−イル)メチルエステル塩酸塩を40%マウ
ス血液中で3フCに5分間インキュベートしたのちバイ
オオートグラフィーを実施し九ところ該エステルは全て
アンピシリンに転化している事が判った。
1750 (carganyl), 1690 (amide) This ampicillin (5-methyl-2-oxo-1,3-f/oxolen-4-yl) methyl ester hydrochloride was added to 40% mouse blood for 5 minutes at 3°C. After incubation, bioautography was performed and it was found that all of the ester had been converted to ampicillin.

Claims (5)

【特許請求の範囲】[Claims] (1)  一般式 (式中、R1は水素原子、低級アルキル基又はアリール
基を示し、Lは水素原子でめるか又祉R1はR1と訳素
鎖で環状に結合している)で示される化合物Vcハpグ
ン化剤を反応せしめること1%(式中Xはへロrン原子
を示し、R,、R,lよ前記に同じ。) で示すれる1、3−ジオキソレン−2−オン訪碑体の製
造法。
(1) It is represented by the general formula (in the formula, R1 represents a hydrogen atom, a lower alkyl group, or an aryl group, L is a hydrogen atom, or R1 is cyclically bonded to R1 through a chain). 1% (In the formula, X represents a heron atom, and R, R, and l are the same as above.) Method of manufacturing On-visit monuments.
(2)ハロダン化剤が塩素化剤又祉臭素化剤である%l
F’Flli1i求の範囲第1項に記載の製造法。
(2) %l in which the halodanizing agent is a chlorinating agent or a brominating agent
F'Flli1i The manufacturing method according to item 1.
(3)  反応を非プロトン性不活性有機溶媒中で行う
特許ir#氷の範囲第1穂又は鮎2項にIC載の鯨足法
(3) Patented IR# ice range first panicle or sweetfish second term IC-listed whale foot method in which the reaction is carried out in an aprotic inert organic solvent.
(4)非プロトン性不活性有機溶媒として級化水素又は
ハロダン化炭化水素を用いる特計錆求O範!28第3項
に記載の製造法。
(4) Special rust-seeking model using graded hydrogen or halodanized hydrocarbon as the aprotic inert organic solvent! 28. The manufacturing method according to paragraph 3.
(5)反応をラジカル肪起剤の存在1本しくは紫外線照
射下に行う特許請求の範囲組1項乃至第4項のい・ずれ
かに記載の製造法。
(5) The production method according to any one of claims 1 to 4, in which the reaction is carried out in the presence of a radical fat-inducing agent or under ultraviolet irradiation.
JP58013076A 1983-01-29 1983-01-29 Preparation of 1,3-dioxolen-2-one derivative Granted JPS58150585A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP58013076A JPS58150585A (en) 1983-01-29 1983-01-29 Preparation of 1,3-dioxolen-2-one derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58013076A JPS58150585A (en) 1983-01-29 1983-01-29 Preparation of 1,3-dioxolen-2-one derivative

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP55058510A Division JPS6019908B2 (en) 1980-04-30 1980-04-30 1,3-dioxolen-2-one derivative

Publications (2)

Publication Number Publication Date
JPS58150585A true JPS58150585A (en) 1983-09-07
JPH0258271B2 JPH0258271B2 (en) 1990-12-07

Family

ID=11823061

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58013076A Granted JPS58150585A (en) 1983-01-29 1983-01-29 Preparation of 1,3-dioxolen-2-one derivative

Country Status (1)

Country Link
JP (1) JPS58150585A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5874677A (en) * 1981-10-30 1983-05-06 Kanebo Ltd Preparation of brominated 1,3-dioxolene-2-ones

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5874677A (en) * 1981-10-30 1983-05-06 Kanebo Ltd Preparation of brominated 1,3-dioxolene-2-ones
JPH0261470B2 (en) * 1981-10-30 1990-12-20 Kanebo Ltd

Also Published As

Publication number Publication date
JPH0258271B2 (en) 1990-12-07

Similar Documents

Publication Publication Date Title
EP0039477B1 (en) Use of 1,3-dioxolen-2-one derivatives
CA1094545A (en) Cephalosporin antibiotics
DE2760287C2 (en)
NO130395B (en)
EP0061206B1 (en) 6-aminopenicillanic acid esters and their use for producing new ampicillin esters
DE2153799A1 (en) Indoline derivatives
US4428806A (en) Process for producing brominated 1,3-dioxolen-2-ones
CH617689A5 (en)
JPS58150585A (en) Preparation of 1,3-dioxolen-2-one derivative
JP3207017B2 (en) Method for producing benzylsuccinic acid derivative and intermediate for producing the same
CN1328265C (en) Method for preparing trifluoromethyl benzothiazole
US4416891A (en) Ester of 6-[(hexahydro-1H-azepin-1-yl)methyleneamino]penicillanic acid, and its use as antibacterial agent
JPS63126873A (en) 4-bromomethyl-5-methyl-1,3-dioxolen-2-one
CA1238311A (en) 6-aminopenicillanic acid esters
JPH0476968B2 (en)
DE3606900A1 (en) TRICYCLIC CONDENSED DIBENZO DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
JPS626552B2 (en)
JPH0967292A (en) Production of benzaldehyde derivative
JPH115764A (en) 15-deoxy-isocarbacycline derivative
GB1572993A (en) Ester derivatives of cefuroxime
JPS606947B2 (en) Adamantane derivative
SU1028667A1 (en) Omega-bicyclic derivative of norprostanic acid having spasmolytic effect
JP3053714B2 (en) Method for producing phenyl 2- (furfurylthio) acetate derivative
JPS61218588A (en) Interfuranylene-prostacycline derivative, manufacture and medicinal composition
US3769296A (en) 3-oxa-1-azaspiro(4,4)non-7-ene-2,4-dione and derivatives thereof